No Data
No Data
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks were higher Wednesday afternoon, with the NYSE Health Care Index adding 1.1% and the Health Care Select Sector SPDR Fund (XLV) rising 1.3%. The iShares Biotechnology ETF (IBB) gaine
CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The CASI Pharmaceuticals (CASI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $6.00.
HC Wainwright & Co. : The CASI Pharmaceuticals (CASI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $6.00.
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $6
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $12 to $6.
CASI Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 83.49% HC Wainwright & Co. $12 → $6 Maintains Buy 11/15/2023 266.97% HC Wainwright & Co. $10 →
Casi Pharma Spikes as FDA Clears Clinical Trial for Blood Disorder Therapy